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Background. We assessed the prevalence, incidence, and predictors of renal impairment among people living with HIV 
(PLWHIV) in rural Tanzania.
Methods. In a cohort of PLWHIV aged ≥15 years enrolled from January 2013 to June 2016, we assessed the association between 
renal impairment (estimated glomerural filtration rate < 90 mL/min/1.73 m2) at enrollment and during follow-up with demographic 
and clinical characteristcis using logistic regression and Cox proportional hazards models.
Results. Of 1093 PLWHIV, 172 (15.7%) had renal impairment at enrollment. Of 921 patients with normal renal function at 
baseline, 117 (12.7%) developed renal impairment during a median follow-up (interquartile range) of 6.2 (0.4–14.7) months. The 
incidence of renal impairment was 110 cases per 1000 person-years (95% confidence interval [CI], 92–132). At enrollment, logistic 
regression identified older age (adjusted odds ratio [aOR], 1.79; 95% CI, 1.52–2.11), hypertension (aOR, 1.84; 95% CI, 1.08–3.15), 
CD4 count <200 cells/mm3 (aOR, 1.80; 95% CI, 1.23–2.65), and World Health Organization (WHO) stage III/IV (aOR, 3.00; 95% 
CI, 1.96–4.58) as risk factors for renal impairment. Cox regression model confirmed older age (adjusted hazard ratio [aHR], 1.85; 
95% CI, 1.56–2.20) and CD4 count <200 cells/mm3 (aHR, 2.05; 95% CI, 1.36–3.09) to be associated with the development of renal 
impairment.
Conclusions. Our study found a low prevalence of renal impairment among PLWHIV despite high usage of tenofovir and its 
association with age, hypertension, low CD4 count, and advanced WHO stage. These important and reassuring safety data stress the 
significance of noncommunicable disease surveillance in aging HIV populations in sub-Saharan Africa.
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Widespread use of antiretroviral treatment (ART) has reduced 
the incidence of opportunistic infections among HIV-infected 
patients dramatically—hence improving health and life expect-
ancy to near normal [1, 2]. As the HIV-infected population 
is aging, the causes of morbidity and mortality among HIV-
infected patients are shifting from opportunistic infections to 
noninfectious disorders such as liver, cardiovascular, and kid-
ney diseases [3]. Kidney dysfunction among HIV patients has 
been reported to be associated with increased morbidity and 
mortality [4, 5].
In sub-Saharan Africa (SSA) the prevalence of kidney dys-
function in people living with HIV (PLWHIV) has been shown 
to be high—ranging from 25% to 77% [6–9]. Contributing 
factors to renal impairment are the high rate of patients with 
hypertension and diabetes mellitus, as well as co-infections 
[10] and chronic use of nephrotoxic drugs such as tenofovir 
disoproxil fumarate (TDF), atazanavir/ritonavir (ATV/r), and 
lopinavir/ritonavir (LPV/r) [11–13]. TDF is widely used in SSA 
as a first line ART due to its high efficacy and low side effects 
and its simultaneous effect against hepatitis B infection [14, 15].
Data on kidney function in PLWHIV from rural SSA regions 
are scarce, and almost no data in longitudinal cohorts are 
available. The Kilombero and Ulanga Antiretroviral Cohort 
(KIULARCO) offers a perfect setting to study prevalence rates 
and predictors of renal impairment among newly diagnosed 
PLWHIV and incidence rates of renal impairment during fol-
low-up in a rural SSA setting [16, 17].
METHODS
Study Design
We conducted a prospective cohort study among HIV-infected 
patients attending the Chronic Diseases Clinic of Ifakara 
(CDCI) at the Saint Francis Referral Hospital in Ifakara. All 
patients attending the CDCI were invited to participate in the 
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Kilombero and Ulanga Antiretroviral Cohort (KIULARCO), 
a cohort established 2005 comprising almost 9000 enrolled 
patients and around 3500 patients on active follow-up [16, 17]. 
The CDCI serves the population from 2 different districts in 
southwestern Tanzania, namely the Kilombero and Ulanga dis-
tricts in the Morogoro region. According to the last census in 
2012, the population of the Kilombero district is 407 880 and 
that of the Ulanga district is 265 203 [18].
Study Population
All newly diagnosed ART-naïve HIV-infected patients 
enrolled in KIULARCO between January 2013 and June 2016 
who met the following criteria were included in this analysis: 
age ≥15 years, availability of a serum creatinine measurement 
at enrollment, at least 1 control creatinine measurement dur-
ing follow-up, and the availability of a signed informed consent. 
The last date of follow-up was June 30, 2016.
Laboratory and Clinical Investigations
Demographic, clinical, laboratory, and pharmaceutical data pro-
spectively collected within KIULARCO were extracted from the 
electronic database. In brief, enrolled patients undergo clinical 
assessment and baseline investigations on the same day. The 
baseline laboratory investigations include CD4 T-cell count (BD 
FACS Calibur, Franklin Lakes, NJ), complete blood cell count, 
aspartate aminotransferase, and alanine aminotransferase. 
Serum creatinine was measured using the Cobas c 111 Analyzer 
(Roche Diagnostics, Rotkreuz, Switzerland), which uses absorp-
tion photometry to determine the amount of absorbance and 
uses it to calculate the concentration in the sample solution. 
Laboratory examinations are repeated routinely twice a year 
unless additionally requested upon clinical indication. The esti-
mated glomerular filtration rate (eGFR) was calculated using 
the Chronic Kidney Diseases Epidemiology (CKD-EPI) formula 
with the ethnicity factor included in the calculation. According to 
“Kidney Disease: Improving Global Outcome” (KDIGO), renal 
impairment was categorized as either mild (eGFR, 60–89 mL/
min/1.73 m2), moderate (eGFR, 30–59  mL/min/1.73 m2), or 
severe (eGFR < 30 mL/min/1.73 m2) [19].
Blood pressure (BP) was measured at every clinic visit. 
Hypertension was defined as having a systolic BP of ≥140 mmHg 
and/or a diastolic BP  ≥90 on 2 consecutive visits measured 
while sitting, having a history of hypertension, or currently tak-
ing antihypertensive medications [20].
Body mass index (BMI) was calculated using weight in kilo-
grams divided by the square of the height in meters. It was cat-
egorized as underweight (BMI  <  18.5  kg/m2), normal weight 
(18.5–24.9 kg/m2), and overweight (≥25 kg/m2) [21].
Tuberculosis (TB) was defined as either having a recorded 
positive GeneXpert (Cepheid, Sunnyvale, CA) in the sputum or 
another body fluid sample, or a chest x-ray suggesting tubercu-
losis together with at least 1 TB symptom, or receiving antitu-
berculosis treatment.
Statistical Analysis
Continuous variables are presented using median and inter-
quartile range (IQR). Categorical variables are presented as 
frequencies and percentages. The outcome variable of renal 
impairment was defined as having an eGFR below 90  mL/
min/1.73 m2. We used a logistic regression model to assess the 
predictors of renal impairment at enrollment.
We performed Cox regression to assess the association 
between baseline covariates and the development of renal 
impairment. Patients who had renal impairment at enrollment 
were excluded from this analysis. Kaplan-Meier estimates were 
used to describe the cumulative probability of developing renal 
impairment according to the exposure status and were com-
pared using the log-rank test.
In multivariate analyses, we a priori identified and included 
potential predictors of renal impairment; age, sex, BMI, HIV 
World Health Organization (WHO) stage, CD4 counts, hyper-
tension, ART use, and TB diagnosis.
All analyses were done with Stata, version 14 (Stat Corp, 
College Station, TX).
Ethics Statement
All study participants provided written informed consent at 
enrollment in KIULARCO. Ethical approval was obtained from 
the Ifakara Health Institute review board, the National Health 
Research Committee of the National Institute of Medical 
Research of Tanzania, the Tanzania Commission of Science 
and Technology, and the Ethikkomission Nordwest und 
Zentralschweiz (EKNZ; Switzerland).
RESULTS
A total of 2267 patients were enrolled in KIULARCO from 
January 2013 to June 2016. A  total of 1093 (48.2%) patients 
could be included in this analysis, and 1174 (51.58%) were 
excluded for the following reasons: 388 (17.1%) were already 
on ART, 284 (12.5%) did not have serum creatinine measure-
ment at enrollment, 392 (17.3%) did not have at least 1 control 
creatinine measurement during follow-up, and 110 (4.8%) were 
younger than age 15 years at enrollment (Figure 1). We did not 
find any difference between patients without and those with a 
creatinine measurement (Supplementary Table 1).
Baseline demographic and clinical characteristics of all 
patients are summarized in Table  1. Overall, 66% of patients 
were female, median age (IQR) was 39 (32.3–47.0) years. 
Median BMI (IQR) was 20.9 (18.9–23.4) kg/m2; of these, 21.5%, 
60.7%, and 16.4% were underweight, normal weight, and over-
weight, respectively. The median CD4 count (IQR) was 207 
(77–378) cells/mm3, with 47.8% of patients presenting with a 
CD4 count of <200 cells/mm3. An advanced HIV disease stage 
(WHO stage III or IV) at enrollment was present in 45.4% of 
patients. A  total of 196 patients (17.9%) were diagnosed with 
TB, and 114 patients (10.4%) were diagnosed with hypertension 
at enrollment.
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Among the 999 (91.2%) patients who started ART, median 
time from enrollment to start of therapy (IQR) was 14 (6–35) 
days. The majority of these patients (676, 61.9%) started ART 
with a single tablet combination of tenofovir disosproxil fuma-
rate (TDF), lamivudine (3TC), and efavirenz (EFV), followed 
by 251 patients (23.0%) on a single tablet combination of TDF, 
emtricitabine (FTC), and EFV. Additionally, there were 33 
patients (3.0%) who had moderate or severe renal impairment 
(eGFR < 60 mL/min/1.73 m2) at enrollment, but they were still 
prescribed a TDF-based regimen. Patients who started ART 
with non-TDF-based regimens (n  =  68 [6.2%] had a lower 
median eGFR at enrollment compared with those with TDF-
based regimens (median eGFR, 105.7 vs 128.3 mL/min/1.73 m2; 
P < .001).
At the end of the study period, 773 patients (70.7%) were still 
under active follow-up, 183 patients (16.7%) were lost to fol-
low-up, 62 patients (5.7%) had died, and 75 patients (6.9%) had 
been transferred to other health facilities. The median length 
of follow-up among those who had normal kidney function at 
enrollment (IQR) was 6.2 (0.4–14.7) months compared with 2.0 
(0.2–8.8) months in those with renal impairment (P < .001).
Predictors of Renal Impairment at Enrollment
Median eGFR at enrollment (IQR) was 126.8 (104.8–140.1) mL/
min/1.73 m2, and 15.7% (172/1093) had renal impairment, defined 
as eGFR <90 mL/min/1.73 m2. Among patients with renal impair-
ment, 9.1%, 3.9%, and 2.7% had mild, moderate, and severe renal 
impairment, respectively. Among 172 patients who had renal impair-
ment at enrollment, 129 (75%) had improved renal function during 
follow-up visits to eGFR above 90  mL/min/1.73 m2. The median 
time to normalize renal function (IQR) was 6.8 (2.3–15.4) months.
In the logistic regression model to determine independent 
predictors of renal impairment at enrollment, the multivaria-
ble analysis (Table 2) showed a significant association between 
renal impairment and older age (per 10-year increase), with an 
adjusted odd ratio (aOR) of 1.79 (95% confidence interval [95% 
CI], 1.52–2.11; P < .001). Furthermore, patients who were diag-
nosed with hypertension at enrollment had almost twice the risk 
2267 patients
enrolled in KIULARCO
388 patients already
on ART at enrollment
1879 ART-naïve
patients at enrollment
284 Patients had no creatinine
measurement at enrollment
1595 patients had creatinine
measurements at enrollment
1485 patients age
≥15 years
392 Patients with single creatinine
measurement at enrollment and no
follow-up creatinine measurement
1093 Patients with single creatinine
measurement at enrollment and at least
1 measurement during follow-up
110 patients age
<15 years
Figure 1. Patients’ flow chart.
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of having renal impairment compared with those who were non-
hypertensive (aOR, 1.84; 95% CI, 1.08–3.15; P =  .026). A CD4 
count <200 cells/mm3 (aOR, 1.80; 95% CI, 1.23–2.65; P = .003) 
and advanced HIV disease (WHO stage III/IV; aOR, 3.00; 95% 
CI, 1.96–4.58; P < .001) were also associated with renal impair-
ment. We did not find any association with sex, BMI, or TB.
Renal Impairment During Follow-up
Figure  2 shows the plotted evolution of eGFR over time of 
all the patients who were enrolled in our study. There was a 
significant improvement in eGFR during the follow-up visits 
(P < .001). In 117 patients (12.7%), kidney function worsened 
(–53. 7 mL/min/1.73 m2; IQR, –77 to –29.6) within a median 
follow-up (IQR) of 5.7 (1.8–9.2) months. Total time at risk was 
1062 person-years, and the incidence of renal impairment was 
110 cases per 1000 person-years (95% CI, 92–132). Among 
these patients, 8.5%, 2.3%, and 2.0% had mild, moderate, and 
severe renal impairment, respectively. The incidence rate for 
developing moderate and severe renal impairment was 37 cases 
per 1000 person-years, (95% CI, 27–50).
Table 1. Baseline Characteristics of the Patients Involved in the Study
Total Cohort
 (n = 1093)
Renal Impairment at 
Baseline (eGFR < 90) 
(n = 172)
Normal Renal Function 
at Baseline (n = 921)
Normal Renal Function 
During Follow-up 
(n = 804)
Renal Impairment During 
Follow-up (eGFR < 90) 
(n = 117)
Sex, No. (%)
 Male 376 (34.4) 69 (40.1) 307 (33.3) 264 (32.8) 43 (36.7)
 Female 717 (65.6) 103 (59.9) 614 (66.7) 540 (67.2) 74 (63.3)
Age, median (IQR), y 39.0 (32.3–47.0) 46.2 (38.9–55.8) 37.9 (31.6–45.6) 37.3 (31.3–44.3) 45.6 (36.2–54.3)
WHO stage, No. (%)
 I 417 (38.2) 26 (15.1) 391 (42.5) 351 (43.7) 40 (34.2)
 II 159 (14.6) 21 (12.2) 138 (15.0) 122 (15.2) 16 (13.7)
 III 327 (29.9) 73 (42.4) 254 (27.6) 221 (27.5) 33 (28.2)
 IV 169 (15.5) 46 (26.7) 123 (13.4) 95 (11.8) 28 (23.9)
BMI
Median (IQR), kg/m2 20.9 (18.9–23.4) 20.6 (18.3–23.4) 20.9 (18.9–23.4) 21.0 (19.0–23.6) 19.9 (18.1–22.6)
 <18.5, No. (%) 235 (21.5) 45 (26.2) 190 (20.6) 158 (19.7) 32 (27.4)
 ≥18.5–24.9, No. (%) 663 (60.7) 97 (56.4) 566 (61.5) 496 (61.7) 70 (59.8)
 ≥25, No. (%) 179 (16.4) 27 (15.7) 152 (16.5) 139 (17.3) 13 (11.1)
CD4 count
Median (IQR), cells/mm3 207 (77–378) 125 (48–267) 221 (87–393) 229 (93–402) 146 (48–311)
 <200, No. (%) 522 (47.8) 106 (61.6) 416 (45.2) 344 (42.8) 72 (61.5)
 ≥200, No. (%) 549 (50.2) 61 (35.5) 488 (53.0) 443 (55.1) 45 (38.5)
CD4 
Median (IQR), % 11 (5.0–19.0) 7.4 (4.0–14.5) 12.0 (6.0–20.0) 12.1 (6.0–20.0) 8 (4.0–17.0)
Tuberculosis, No. (%)
 Yes 196 (17.9) 46 (26.7) 150 (16.3) 134 (16.7) 16 (13.7)
 No 875 (80.1) 124 (72.1) 751 (81.5) 652 (81.1) 99 (84.6)
Hypertension, No. (%)
 Yes 114 (10.4) 26 (15.1) 88 (9.6) 71 (8.8) 17 (14.5)
 No 962 (88.0) 140 (81.4) 822 (89.3) 724 (90.1) 98 (83.8)
First ART started, No. (%)
 AZT+3TC+NVP 11 (1.0) 3 (1.7) 8 (0.9) 8 (1.0) 0
 AZT+3TC+EFV 40 (3.7) 13 (7.6) 27 (3.18) 24 (3.0) 3 (2.6)
 TDF+FTC+EFV 251 (23.0) 24 (14.0) 227 (26.7) 193 (24.0) 34 (29.1)
 TDF+FTC+NVP 1 (0.1) 0 1 (0.12) 0 1 (0.9)
 TDF+3TC+EFV 676 (61.9) 94 (54.7) 582 (63.2) 514 (63.9) 68 (58.1)
 ABC+3TC+EFV 16 (1.5) 14 (8.1) 2 (0.2) 0 2 (1.7)
 TDF/FTC/LPV/r 1 (0.1) 0 1 (0.1) 1 (0.1) 0
 AZT+3TC+LPV/r 1 (0.1) 1 (0.6) 0 0 0
 TDF+FTC+ATV/r 2 (0.2) 0 2 (0.2) 1 (0.1) 1 (0.9)
Time under observation
Median (IQR), mo 6.2 (0.4–14.7) 12.8 (6.2–21.9) 5.7 (1.8–9.2)
We had 93.2% of patients starting on a TDF-based regimen, 2 patients on an LPV/r regimen, and 2 patients on ATV/r. 
Abbreviations: 3TC, lamivudine; ABC, abacavir; ART, antiretroviral treatment; ATV/r, atazanavir/ritonavir; AZT, zidovudine; BMI, body mass index; EFV, efavirenz; eGFR, estimated glomerular 
filtration rate; FTC, emtricitabine; IQR, interquartile range; LPV/r, lopinavir/ritonavir; LTFU, loss to the follow-up; NVP, nevirapine; TDF, tenofovir disoproxil fumarate; WHO, World Health 
Organization. 
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The Kaplan-Meier estimates showed that the proportion 
of patients developing renal impairment was higher among 
patients older than age 50  years (compared with those aged 
50 years and younger: 28.5 vs 9.6%; log-rank P < .001), among 
patients with BMI <18.5  kg/m2 (compared with those with 
BMI ≥  18.5  kg/m2: 16.8% vs 11.6%; log-rank P  <  .041), and 
among patients diagnosed with hypertension compared with 
those without (19.3% vs 11.9%; log-rank P = .054). Additionally, 
the proportion of patients developing renal impairment was 
higher among patients with WHO stage III/IV compared with 
WHO stage I/II (16.2% vs 10.6, respectively; log-rank P = .001) 
and those patients with advanced immunosuppression (CD4 < 
200 compared with those with CD4 ≥ 200 cells/mm3, 17.3% vs 
9.2%, respectively; log-rank P = .0002).
Table  3 shows results of Cox regression modeling for risk 
factors associated with the development of renal impairment 
during follow-up visits. Factors associated with increased 
risk of renal impairment in the multivariate analysis included 
older age (per 10-year increase; adjusted hazard ratio [aHR], 
1.85; 95% CI, 1.56–2.20; P <  .001) and CD4 count <200 cells/
mm3 (aHR, 2.05; 95% CI, 1.36–3.09; P  =  .001). Additionally, 
we found a trend for an association between the development 
of renal impairment and both WHO stage III/IV (aHR, 1.47; 
95% CI, 0.97–2.25; P = .072) and TB (aHR, 0.60; 95% CI, 0.34–
1.05; P = .076). We did not find any association between renal 
impairment and sex, BMI, hypertension, or use of ART during 
follow-up. TDF use could not be analyzed as a risk factor as 
93.2% of patients received TDF as part of first  line treatment. 
The final model had a good fit and met the proportional hazard 
assumption (Schoenfeld’s global P = .521).
DISCUSSION
In our prospective study among 1093 adult HIV-infected 
patients in rural Tanzania followed for 1062 person-years, 
we found a prevalence of renal impairment of 15.7% in treat-
ment-naïve patients. Among patients with normal renal func-
tion at enrollment, the incidence rate of developing moderate 
and severe renal impairment during follow-up was low, with 37 
cases per 1000-person years (95% CI, 27–50).
We found a lower prevalence of renal impairment compared 
with previous studies done in SSA, which documented preva-
lence ranging from 25% to 77% [6–9]. This could be because in 
previous studies more patients were diagnosed with advanced 
HIV disease (WHO stage III or IV and lower CD4 cell counts) 
compared with our study.
In our study, after adjusting for potential confounders (sex, 
hypertension, CD4 count, BMI, WHO stage, and TB), age at 
enrollment (per 10-year increase) remained associated with a 
79% higher risk of renal impairment. Likewise, we found that 
arterial hypertension at enrollment led to almost twice the 
odds of renal impairment. This is in line with results from a 
study among HIV patients in Italy [22]. But also, parameters of 
advanced HIV disease at enrollment (CD4 count < 200 cells/
mm3 and WHO stage III or IV) had a higher odds of renal 
impairment, as previously reported by Mulenga et  al. and 
Gallant et al. [23, 24]. We did not find any association between 
renal impairment and TB, as reported previously [25].
In contrast, incident renal impairment while on antiretroviral 
treatment was slightly higher compared with a study done in 
Spain that found 29 cases per 1000 person-years and was lower 
compared with another study done in Myanmar that found an 
incidence rate of 54 cases per 1000 person-years [26, 27]. The 
wide coverage of ART in HIV patients in SSA and the associated 
decrease in mortality and increase in patient age has led to an 
increased risk of developing other comorbidities, such as hyper-
tension, diabetes mellitus, and renal impairment [1–3, 28].
For predictors of renal impairment during follow-up, we 
performed a Cox proportional hazard model. In the adjusted 
Cox regression model, we found a strong association between 
renal impairment and increased age, as well as presenting with 
low CD4 count at enrollment. These results go in line with a 
recent study published by Hamzah et al., although they found 
kidney dysfunction to be more common among patients with 
white ethnicity compared with other ethnicities [29]. We found 
a positive association between developing renal impairment 
and presenting with WHO stage III or IV at enrollment and 
a negative association between renal impairment and being 
diagnosed with TB at enrollment, although both factors were 
not statistically significant. Furthermore, we found that the risk 
Table  2. Univariate and Multivariate Logistic Regression Model for 
Predictors of Renal Impairment at Baseline
Variable
Univariate Model 
Unadjusted OR 
(95% CI) P Value
Multivariate Model
Adjusted OR  
(95% CI) P Value
Age, per 10 y 1.81 (1.56–2.09) <.001 1.79 (1.52–2.11) <.001
Female sex 0.75 (0.53–1.04) .086 1.22 (0.83–1.80) .313
BMI, kg/m2
 ≥18.5 1 1
 <18.5 1.37 (0.94–2.00) .100 0.82 (0.53–1.27) .383
CD4 count, cells/mm3
 ≥200 1 1
 <200 2.04 (1.45–2.87) <.001 1.80 (1.23–2.65) .003
Hypertension
 No 1 1
 Yes 1.73 (1.08–2.78) .022 1.84 (1.08–3.15) .026
WHO stage
 I or II 1 1
 III or IV 3.55 (2.47–5.11) <.001 3.00 (1.96–4.58) <.001
Tuberculosis diagnosis
 No 1 1
 Yes 1.86 (1.27–2.72) .001 1.09 (0.70–1.71) .691
Abbreviations: BMI, body mass index; CI, confidence interval; OR, odds ratio; WHO, 
World Health Organization. 
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of renal impairment development was 44% lower among those 
who started ART during follow-up compared with those who 
did not start, although this was not statistically significant.
Among 29 patients who had severe renal impairment 
(eGFR < 30 mL/min) at enrollment, kidney function normal-
ized (eGFR  ≥  60  mL/min) during follow-up in 23 patients 
(79%), 3 patients died, and another 3 patients were lost to fol-
low-up. Additionally, more than 75% of patients who had renal 
impairment at enrollment normalized within a median time of 
6 months; most likely, this was caused by acute kidney injury 
rather than chronic kidney disease (CKD).
Our study has several limitations. Renal impairment was 
based on 1 creatinine measurement only; hence we could not 
differentiate between acute and chronic kidney diseases. We 
acknowledge it is a common practice to define CKD as having 
at least 2 eGFR measurements <60 mL/min/1.73 m2 more than 
3 months apart, but in resource-limited settings, this is a chal-
lenge, mainly because transport costs for patients do not allow 
extra visits [6, 9, 24]. Among the 921 patients with 2 consecu-
tive eGFR measurements available, only 20 (2.2%) developed 
at least 2 episodes of eGFR  <60  mL/min/1.73 m2 during fol-
low-up and only 1 developed CKD. Therefore, our study results 
should be interpreted with caution as they show loss of kidney 
dysfunction rather than CKD. Also, in our setting, we do not 
routinely measure viral load, glycosuria, serum glucose, and 
proteinuria, which have been reported to be associated with 
renal impairment [30, 31]. Another possible confounder, for 
which we did not collect information, is the use of traditional 
medicines, which according a recent survey done in Tanzania 
has been shown to be a common practice, involving around 
70% of patients with CKD in the community [32]. Similarly, 
we could not analyze if the renal impairment developed by our 
patients during follow-up was associated with TDF use as the 
majority of our patients who started ART (93.2%) also started 
treatment with a TDF-based regimen. Also, as almost a quarter 
of our patients presented with a BMI <18.5 kg/m2, the calcula-
tions of eGFR might have been underestimated. For practica-
bility, we had to decide on 1 formula, despite the fact that this 
might have been inappropriate for certain subgroups of patients 
and specific phases of HIV infection.
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Figure 2. Evolution of eGFR among patients after enrollment. Average evolution of eGFR among patients. A, All patients. B, Patients presented with eGFR <90 mL/min/1.73 
m2. C, Patients with eGFR <60 mL/min/1.73 m2. D, Patients with eGFR <30 mL/min/1.73 m2. Abbreviations: eGFR, estimated glomerular filtration rate, CI, confidence interval.
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Despite these limitations, we believe that our study has clin-
ical and public health implications due to its prospective study 
design and comprehensive information on noncommunicable 
diseases (NCDs), such as hypertension and kidney disease. 
Awareness of the importance of NCDs in the community is 
still lacking [33–36], which has been shown in recent survey 
in Tanzania that reported that only 10.5% of affected persons 
were aware of an underlying CKD [37]. In most parts of sub-Sa-
haran Africa, NCDs are not routinely screened due to lack of 
resources, and health care settings are not yet prepared for the 
management of chronic diseases other than HIV. Additionally, 
there are very few cohorts in Africa where evaluation of long-
term outcomes of chronic diseases can be assessed. According 
to the Tanzania National Guideline for the Management of HIV 
and AIDS, screening for NCDs among HIV-infected patients is 
strongly recommended. However, in reality, unfortunately, this 
is usually not the practice in most HIV clinics in the country due 
to lack of reagents and a separation between chronic diseases 
clinics and HIV clinics. Also, as in most of the HIV clinics nurses 
are providing ART to the patients, they do not usually perform 
routine checking of NCDs. A  study from Cambodia showed 
that combining HIV treatment programs with NCD control 
programs is beneficial [38]. Additionally, most studies in SSA 
have used Cockcroft-Gault or the Modification of Diet in Renal 
Diseases equation (MDRD) for calculation of the eGFR instead 
of the CKD-EPI equation [6, 8, 24]. The CKD-EPI equation is 
as precise as the MDRD equation in the subgroup of patients 
with eGFRs lower than 60 mL/min/1.73 m2; however, it is more 
accurate in patients with eGFRs above 60  mL/min/1.73 m2 
and is the recommended formula in population screening 
where CKD status is unknown [39, 40].
CONCLUSION
Our study found a low prevalence of renal impairment among 
HIV-infected patients despite high usage of TDF and an asso-
ciation of renal impairment with age, hypertension, low CD4 
count, and advanced WHO stage. Our results are important and 
provide reassuring safety data, and they stress the significance of 
surveillance of noncommunicable diseases such as hypertension 
in an aging HIV population in SSA. Combining HIV programs 
with other noncommunicable disease control programs should 
be the way forward for better outcomes in HIV-infected patients.
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